vs

Side-by-side financial comparison of Chanson International Holding (CHSN) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $8.7M, roughly 1.4× Chanson International Holding). Chanson International Holding runs the higher net margin — -12.1% vs -1398.3%, a 1386.3% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 15.2%).

Chanson International Holding is a food and beverage enterprise focused on operating premium bakery chains primarily across mainland China. Its product portfolio includes freshly baked bread, handcrafted pastries, custom celebration cakes, specialty beverages, and frozen bakery goods supplied to partnered retail outlets, catering to middle-class consumers with demand for high-quality daily food options.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

CHSN vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.4× larger
RNA
$12.5M
$8.7M
CHSN
Growing faster (revenue YoY)
RNA
RNA
+418.8% gap
RNA
434.0%
15.2%
CHSN
Higher net margin
CHSN
CHSN
1386.3% more per $
CHSN
-12.1%
-1398.3%
RNA

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
CHSN
CHSN
RNA
RNA
Revenue
$8.7M
$12.5M
Net Profit
$-1.0M
$-174.4M
Gross Margin
44.5%
Operating Margin
-13.7%
-1513.5%
Net Margin
-12.1%
-1398.3%
Revenue YoY
15.2%
434.0%
Net Profit YoY
-4579.7%
-117.0%
EPS (diluted)
$-2.87
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHSN
CHSN
RNA
RNA
Q3 25
$12.5M
Q2 25
$8.7M
$3.8M
Q1 25
$1.6M
Q4 24
$3.0M
Q3 24
$2.3M
Q2 24
$7.5M
$2.0M
Q1 24
$3.5M
Q4 23
$2.2M
Net Profit
CHSN
CHSN
RNA
RNA
Q3 25
$-174.4M
Q2 25
$-1.0M
$-157.3M
Q1 25
$-115.8M
Q4 24
$-102.3M
Q3 24
$-80.4M
Q2 24
$23.4K
$-70.8M
Q1 24
$-68.9M
Q4 23
$-60.4M
Gross Margin
CHSN
CHSN
RNA
RNA
Q3 25
Q2 25
44.5%
Q1 25
Q4 24
Q3 24
Q2 24
41.5%
Q1 24
Q4 23
Operating Margin
CHSN
CHSN
RNA
RNA
Q3 25
-1513.5%
Q2 25
-13.7%
-4448.7%
Q1 25
-8360.9%
Q4 24
-4069.6%
Q3 24
-4200.9%
Q2 24
-7.4%
-4040.4%
Q1 24
-2178.6%
Q4 23
-3043.5%
Net Margin
CHSN
CHSN
RNA
RNA
Q3 25
-1398.3%
Q2 25
-12.1%
-4089.3%
Q1 25
-7360.0%
Q4 24
-3439.5%
Q3 24
-3441.7%
Q2 24
0.3%
-3461.8%
Q1 24
-1943.4%
Q4 23
-2756.2%
EPS (diluted)
CHSN
CHSN
RNA
RNA
Q3 25
$-1.27
Q2 25
$-2.87
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$0.15
$-0.65
Q1 24
$-0.79
Q4 23
$-0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHSN
CHSN
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$22.1M
$350.2M
Total DebtLower is stronger
$4.5M
Stockholders' EquityBook value
$24.5M
$1.9B
Total Assets
$51.6M
$2.1B
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHSN
CHSN
RNA
RNA
Q3 25
$350.2M
Q2 25
$22.1M
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$4.1M
$575.8M
Q1 24
$471.4M
Q4 23
$185.1M
Total Debt
CHSN
CHSN
RNA
RNA
Q3 25
Q2 25
$4.5M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
Stockholders' Equity
CHSN
CHSN
RNA
RNA
Q3 25
$1.9B
Q2 25
$24.5M
$1.2B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$1.5B
Q2 24
$12.1M
$1.2B
Q1 24
$830.9M
Q4 23
$500.8M
Total Assets
CHSN
CHSN
RNA
RNA
Q3 25
$2.1B
Q2 25
$51.6M
$1.4B
Q1 25
$1.5B
Q4 24
$1.6B
Q3 24
$1.6B
Q2 24
$38.7M
$1.3B
Q1 24
$951.5M
Q4 23
$628.6M
Debt / Equity
CHSN
CHSN
RNA
RNA
Q3 25
Q2 25
0.18×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHSN
CHSN
RNA
RNA
Operating Cash FlowLast quarter
$-390.3K
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHSN
CHSN
RNA
RNA
Q3 25
$-156.2M
Q2 25
$-390.3K
$-199.7M
Q1 25
$-124.8M
Q4 24
$-99.9M
Q3 24
$-65.6M
Q2 24
$806.1K
$-65.0M
Q1 24
$-70.4M
Q4 23
$16.5M
Free Cash Flow
CHSN
CHSN
RNA
RNA
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$771.9K
$-65.5M
Q1 24
$-71.3M
Q4 23
$15.6M
FCF Margin
CHSN
CHSN
RNA
RNA
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
10.2%
-3204.6%
Q1 24
-2012.3%
Q4 23
713.1%
Capex Intensity
CHSN
CHSN
RNA
RNA
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
0.5%
26.0%
Q1 24
25.8%
Q4 23
39.4%
Cash Conversion
CHSN
CHSN
RNA
RNA
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
34.43×
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons